Chimeric antigen receptor T-cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation

Chimeric antigen receptor T-cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation

Chimeric antigen receptor T-cell therapy (CAR-T) has been used to treat refractory post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant patients, including heart, kidney, liver, intestine, and pancreas. We report the use of CAR-T for treating refractory PTLD in a 73-year-old...

Full description

Bibliographic Details
Main Authors: Kaleb Veit, DO, Tahuanty Peña, MD, MS, Julia Klesney-Tait, MD, PhD, Eric Mou, MD, Umar Farooq, MD
Format: Article
Language:English
Published: Elsevier 2024-08-01
Series:JHLT Open
Subjects:
post-transplant lymphoproliferative disorder
lung transplant
lymphoma
chimeric antigen receptor T-cell therapy
CAR-T
Online Access:http://www.sciencedirect.com/science/article/pii/S2950133424000508

Internet

http://www.sciencedirect.com/science/article/pii/S2950133424000508

Similar Items